https://www.selleckchem.com/pr....oducts/LAQ824(NVP-LA
during the COVID-19 pandemic. European Association for the Study of the Liver, US National Institutes of Health, UK National Institute for Health Research. European Association for the Study of the Liver, US National Institutes of Health, UK National Institute for Health Research. Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy
Like
Comment
Share
